Skip to main content
Top

02-11-2023 | Thyroid Cancer | Expert Interview | Article

ESMO 2023: A new option for thyroid cancer

print
PRINT
insite
SEARCH
Host:
Dr. Shreeya Nanda

Dr. Laura Locati comments on the LIBRETTO-531 study of selpercatinib in previously untreated RET-mutant medullary thyroid carcinoma, which has provided a new treatment option for this patient population.

Speaker

  • Dr. Laura Locati
    University of Pavia, Italy
print
PRINT

Related topics

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine